Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts.
about
Targeting intratumoral androgens: statins and beyondStatin derivatives as therapeutic agents for castration-resistant prostate cancer.Identification of simvastatin-regulated targets associated with JNK activation in DU145 human prostate cancer cell death signaling.High expression of SLCO2B1 is associated with prostate cancer recurrence after radical prostatectomy.Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study.
P2860
Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Oral simvastatin administratio ...... aP prostate cancer xenografts.
@en
type
label
Oral simvastatin administratio ...... aP prostate cancer xenografts.
@en
prefLabel
Oral simvastatin administratio ...... aP prostate cancer xenografts.
@en
P2093
P2860
P356
P1476
Oral simvastatin administratio ...... aP prostate cancer xenografts.
@en
P2093
H H Adomat
J A Gordon
M Ghaffari
T L Klassen
P2860
P2888
P356
10.1038/PCAN.2015.37
P577
2015-08-04T00:00:00Z